The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.
S. Verazza, S.D. (2017). Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 15(S1), 125-125.
Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
M. C. Maggio;
2017-01-01
Abstract
The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.
| File | Dimensione | Formato | |
|---|---|---|---|
|
PRES2016_MaggioMC_et_al_P216.pdf
accesso aperto
Descrizione: PRES2016_etanercept
Tipologia:
Versione Editoriale
Dimensione
49.53 kB
Formato
Adobe PDF
|
49.53 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
